Erratum: Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG) (Genetics in Medicine (2023) 25(2), (S1098360022010048), (10.1016/j.gim.2022.11.004))

Correction to: Genetics in Medicine 2022; https://doi.org/10.1016/j.gim.2022.11.004, published online 16 December 2022. In the article “Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)” by Dungan JS et al (Genet Med 2023;25:100336), the following updates were made. After publication of this Guideline, ACMG decided to change the term for this screening from “non-invasive prenatal screening”, and its corresponding acronym, to “prenatal cell-free DNA screening”. Future ACMG publications about this topic will now include the revised terminology. On page 4 (left-hand column), the sentence “Corresponding FPR for those trisomies are 0.07% (95% CI = 0.03%-0.17%) and 0.04% (95% CI = 0.02%-0.08%), respectively (Table 3 in Rose et al).³” was updated to “Corresponding FPR for those trisomies are 0.07% (95% CI = 0.03%-0.17%) and 0.04% (95% CI = 0.02%-0.08%), respectively (Table 1 in Rose et al).³” On page 12, reference 43 was updated to “43. Rousseau F, Langlois S, Johnson J, et al. Prospective head-to-head comparison of accuracy of two sequencing platforms for screening for fetal aneuploidy by cell-free DNA: the PEGASUS study. Eur J Hum Genet. 2019;27(11):1701-1715. http://doi.org/10.1038/s41431-019-0443-0”. The authors would like to apologize for any inconvenience this may have caused. The article has been corrected online and can be accessed at https://doi.org/10.1016/j.gim.2022.11.004.